MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on September 21, 2004; DOI: 10.1124/mol.104.000463


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.000463v1
66/6/1712    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cormier, A.
Right arrow Articles by Grailhe, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cormier, A.
Right arrow Articles by Grailhe, R.


Received for publication March 15, 2004.
Revised September 16, 2004.
Accepted for publication September 16, 2004.

Long-term exposure to nicotine modulates the level and activity of acetylcholine receptors in white blood cells of smokers and model mice

Anne Cormier 1, Yoav Paas 1, Roland Zini 2, Jean-Paul Tillement 2, Gilbert Lagrue 3, Jean-Pierre Changeux 4, Regis Grailhe 1*

1 Institut Pasteur 2 Universite Paris 12 3 Centre de Tabacologie, Albert Chenevier Hospital 4 Institut pasteur

* Address correspondence to: E-mail: regis{at}grailhe.com

Abstract

Chronic consumption of tobacco by smokers causes addiction and increases the level of neuronal nicotinic acetylcholine receptors (nAChRs) in the brain - a phenomenon known as up-regulation. Here, we show that up-regulation of specific nAChR subunits takes place in white blood cells (WBCs) of smokers and mice subjected to chronic administration of nicotine. The basal level of {alpha}-bungarotoxin binding sites ({alpha}-BGT), which correspond to the homomeric {alpha}7 nAChR subtype, was not affected in WBCs of both smokers and mice administered with nicotine. In contrast, epibatidine (EB) binding sites, which correspond to heteromeric nAChR subtypes, were detected in WBCs of smokers but not in WBCs of non-smokers. The number of EB-binding sites significantly decreased after incubation of the smokers' WBCs for three days in nicotine-free culture medium. In WBCs of wild type (WT) mice, basal level of EB binding sites was detected before nicotine administration. This basal level is reduced by ~60 percents in knockout mice lacking the genes encoding either the {beta}2 or the {alpha}4 receptor subunits. Additional analysis of knockout mice revealed that the remaining ~40 percents do not undergo up-regulation, indicating that the {alpha}4/{beta}2 subunits comprise the up-regulated nAChRs. We further found that up-regulation in mouse WBCs is accompanied by a significant decrease in the capacity of the up-regulated receptor channels to convey calcium ions. The phenomenon of nAChR up-regulation in WBC provides a simple tool to evaluate and study tobacco addiction.


Key words: Nicotinic cholinergic, Ca imaging, Receptor binding studies


This article has been cited by other articles:


Home page
J. Leukoc. Biol.Home page
I. Cloez-Tayarani and J.-P. Changeux
Nicotine and serotonin in immune regulation and inflammatory processes: a perspective
J. Leukoc. Biol., March 1, 2007; 81(3): 599 - 606.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
G. Cohen, J.-C. Roux, R. Grailhe, G. Malcolm, J.-P. Changeux, and H. Lagercrantz
From The Cover: Perinatal exposure to nicotine causes deficits associated with a loss of nicotinic receptor function
PNAS, March 8, 2005; 102(10): 3817 - 3821.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics